{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:12:36Z","timestamp":1776355956485,"version":"3.51.2"},"reference-count":18,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Res Paediatr"],"published-print":{"date-parts":[[2017]]},"abstract":"<b><i>Background\/Aims:<\/i><\/b> A meta-analysis was undertaken to assess the effect of triptorelin 11.25 mg 3-month prolonged-release formulation in central precocious puberty (CPP). <b><i>Methods:<\/i><\/b> All available clinical studies with triptorelin 11.25 mg were included. The primary outcome was the proportion of children with suppressed luteinising hormone (LH) response (peak LH \u22643 IU\/L) to the gonadotrophin-releasing hormone (GnRH) test 3 months after triptorelin 11.25 mg injection. Secondary outcomes included: the proportion with suppressed peak LH response at 6 months and the proportion with suppressed peak follicle-stimulating hormone (FSH) response (\u22643 IU\/L), suppressed oestradiol (\u226420 pmol\/L) in girls or suppressed testosterone (\u226430 ng\/dL) in boys at 3 months. <b><i>Results:<\/i><\/b> 153 children (13 boys, 140 girls) were included. The proportion with a suppressed peak LH response to the GnRH test was 87.6% (95% CI: 81.3\u201392.4, <i>p<\/i> &#x3c; 0.0001, for a proportion &#x3e;70%) and 92.8% (95% CI: 87.5\u201396.4, <i>p<\/i> &#x3c; 0.0001, for a proportion &#x3e;70%) at 3 and 6 months, respectively. FSH peak, oestradiol, and testosterone were suppressed in 86.7% (95% CI: 79.1\u201392.4), 97.1% (95% CI: 91.6\u201399.4), and 72.7% (95% CI: 39.0\u201394.0) of children at 3 months, respectively. <b><i>Conclusion:<\/i><\/b> Triptorelin 11.25 mg 3-month formulation is efficacious in suppressing LH peak and other gonadal hormones and in slowing the progression of CPP in children.<\/jats:p>","DOI":"10.1159\/000456545","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T21:05:23Z","timestamp":1492635923000},"page":"224-232","source":"Crossref","is-referenced-by-count":20,"title":["Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation"],"prefix":"10.1159","volume":"87","author":[{"given":"Ad\u00e9la\u00efde","family":"Durand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maith\u00e9","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharat","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Dutailly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1783"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.44.235.291"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/adc.45.239.13"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02056"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198112243052602"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-52-2-370"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.806489"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/583751"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2006.19.8.963"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000448840"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177729756"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01229.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200406040-00002"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2000.13.S1.723"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/beem.2002.0188"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02146.x"}],"container-title":["Hormone Research in Paediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/456545","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/456545","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/456545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:18:16Z","timestamp":1745428696000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000456545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,7,4]]}},"URL":"https:\/\/doi.org\/10.1159\/000456545","archive":["Portico"],"relation":{},"ISSN":["1663-2818","1663-2826"],"issn-type":[{"value":"1663-2818","type":"print"},{"value":"1663-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}